Loading...

Clincial Study Patient Recruitment and Site Engagement

Head and Neck Cancer

Stark Raving Branding and Digital Marketing

Nanoray-312: A Clinical Study for Head and Neck Cancer

SponsorNanobiotix

 

IndicationHead and Neck Cancer

 

MaterialsStudy Branding

 Patient Outreach

 Patient Education

 Site Staff Materials

 Referring Physician

 Patient Retention






NANORAY-312 a global, open-label, two-arm, randomized, Investigator’s Choice phase III registration study that is designed to investigate the efficacy and safety of radiotherapy-activated NBTXR3 with or without cetuximab versus radiotherapy with or without cetuximab in high-risk, chemotherapy-ineligible elderly patients with locally-advanced head and neck squamous cell carcinoma (LA-HNSCC).

Participants in NANORAY-312 were be treated with NBTXR3 at a 1:1 ratio after an Investigator’s Choice of radiotherapy alone or radiotherapy in combination with cetuximab. NANORAY-312 enrolled 500 patients across sites in the United States, Europe, and Asia. The primary endpoint of the pivotal study was Progression-free Survival (PFS) and key secondary endpoints include Overall Survival (OS), response rates, and quality of life.






Stark Raving Branding and Digital Marketing

Let's talk about your next project
To discuss an upcoming project or to learn more about our services, please contact us.

Be sure you complete all fields. Thank you!